NCT00650468

Brief Summary

A study comparing the early withdrawal of steroids to long-term maintenance steroid therapy in Kidney Transplant Patients receiving Prograf and Cellcept

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
397

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Nov 1999

Longer than P75 for phase_4

Geographic Reach
1 country

29 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 1999

Completed
8.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2007

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2007

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

March 17, 2008

Completed
15 days until next milestone

First Posted

Study publicly available on registry

April 1, 2008

Completed
Last Updated

November 17, 2011

Status Verified

March 1, 2009

Enrollment Period

8.1 years

First QC Date

March 17, 2008

Last Update Submit

November 15, 2011

Conditions

Keywords

Renal TransplantationPrograf

Outcome Measures

Primary Outcomes (1)

  • Assessment of death, graft loss, or severe acute rejection

    6 months, 12 months, yearly up to 5 years

Secondary Outcomes (5)

  • Comparison of patient and graf survival

    6 months, 12 months, yearly up to 5 years

  • Incidence and severity of acute rejection

    6 months, 12 months, yearly up to 5 years

  • Need for antilymphocyte treatment

    6 months, 12 months, yearly up to 5 years

  • Graft function

    6 month, 12 months, yearly up to 5 years

  • Framingham Coronary Heart Disease Risk Factors

    6 months, 12 months, yearly up to 5 years

Study Arms (2)

1

EXPERIMENTAL

early steroid cessation

Drug: tacrolimusDrug: CellCeptDrug: steroids (methylprednisone or prednisone)

2

EXPERIMENTAL

long-term maintenance steroids

Drug: tacrolimusDrug: CellCeptDrug: steroids (methylprednisone or prednisone)

Interventions

Oral

Also known as: Prograf, FK506
12

IV or Oral

Also known as: MMF, Mycophenolate mofetil
12

IV or Oral

Also known as: methylprednisone, prednisone
12

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient is between post kidney transplant day 3-7 and no requirement for dialysis

You may not qualify if:

  • Patient is receiving kidney from HLA identical,living donor
  • Patient is a multi-organ transplant recipient
  • Patient is pregnant or lactating. Female patients of child bering potential must have a negative pregnancy test and agree to practice effective birth control

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (29)

Unknown Facility

Little Rock, Arkansas, 72205, United States

Location

Unknown Facility

Loma Linda, California, 92354, United States

Location

Unknown Facility

Los Angeles, California, 90057, United States

Location

Unknown Facility

Denver, Colorado, 80262, United States

Location

Unknown Facility

Chicago, Illinois, 60637, United States

Location

Unknown Facility

Lexington, Kentucky, 40536, United States

Location

Unknown Facility

New Orleans, Louisiana, 70121, United States

Location

Unknown Facility

Baltimore, Maryland, 21201, United States

Location

Unknown Facility

Boston, Massachusetts, 02111, United States

Location

Unknown Facility

Detroit, Michigan, 48202, United States

Location

Unknown Facility

Minneapolis, Minnesota, 55455, United States

Location

Unknown Facility

Rochester, Minnesota, 55905, United States

Location

Unknown Facility

Omaha, Nebraska, 68198, United States

Location

Unknown Facility

New Brunswick, New Jersey, 08903, United States

Location

Unknown Facility

Buffalo, New York, 14203, United States

Location

Unknown Facility

New York, New York, 10021, United States

Location

Unknown Facility

New York, New York, 10029, United States

Location

Unknown Facility

Cincinnati, Ohio, 45267, United States

Location

Unknown Facility

Cleveland, Ohio, 44106, United States

Location

Unknown Facility

Philadelphia, Pennsylvania, 19107, United States

Location

Unknown Facility

Providence, Rhode Island, 02903, United States

Location

Unknown Facility

Memphis, Tennessee, 38163, United States

Location

Unknown Facility

Nashville, Tennessee, 37232, United States

Location

Unknown Facility

Galveston, Texas, 77555, United States

Location

Unknown Facility

San Antonio, Texas, 78229, United States

Location

Unknown Facility

Salt Lake City, Utah, 84103, United States

Location

Unknown Facility

Salt Lake City, Utah, 84132, United States

Location

Unknown Facility

Madison, Wisconsin, 53792, United States

Location

Unknown Facility

Milwaukee, Wisconsin, 53226, United States

Location

Related Publications (4)

  • Woodle ES; Fujisawa Corticosteroid Withdrawal Study Group. A prospective, randomized, multicenter, double-blind study of early corticosteroid cessation versus long-term maintenance of corticosteroid therapy with tacrolimus and mycophenolate mofetil in primary renal transplant recipients: one year report. Transplant Proc. 2005 Mar;37(2):804-8. doi: 10.1016/j.transproceed.2004.12.083.

    PMID: 15848538BACKGROUND
  • Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van Veldhuisen P; Astellas Corticosteroid Withdrawal Study Group. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg. 2008 Oct;248(4):564-77. doi: 10.1097/SLA.0b013e318187d1da.

    PMID: 18936569BACKGROUND
  • Gaber AO, Moore LW, Alloway RR, Woodle ES, Pirsch J, Shihab F, Henning A, Fitzsimmons W, Holman J, Reisfield R, First MR; Astellas Corticosteroid Withdrawal Study Group. Acute rejection characteristics from a prospective, randomized, double-blind, placebo-controlled multicenter trial of early corticosteroid withdrawal. Transplantation. 2013 Feb 27;95(4):573-9. doi: 10.1097/TP.0b013e3182777efb.

  • Delgado JC, Fuller A, Ozawa M, Smith L, Terasaki PI, Shihab FS, Eckels DD. No occurrence of de novo HLA antibodies in patients with early corticosteroid withdrawal in a 5-year prospective randomized study. Transplantation. 2009 Feb 27;87(4):546-8. doi: 10.1097/TP.0b013e3181949d2e.

MeSH Terms

Interventions

TacrolimusMycophenolic AcidSteroidsPrednisone

Intervention Hierarchy (Ancestors)

MacrolidesLactonesOrganic ChemicalsCaproatesAcids, AcyclicCarboxylic AcidsFatty AcidsLipidsFused-Ring CompoundsPolycyclic CompoundsPregnadienediolsPregnadienesPregnanes

Study Officials

  • central contact

    Astellas Pharma US, Inc.

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

March 17, 2008

First Posted

April 1, 2008

Study Start

November 1, 1999

Primary Completion

December 1, 2007

Study Completion

December 1, 2007

Last Updated

November 17, 2011

Record last verified: 2009-03

Locations